Taysha (TSHA) Q1 2026 Earnings Report and Key Financial Highlights
Taysha (TSHA) reported a net loss of $42.4 million for Q1 2026, driven by increased R&D and general administrative expenses. The company holds $276.6 million in cash, sufficient to fund operations through 2028. The FDA confirmed comparability of clinical and commercial manufacturing materials for TSHA-102, supporting BLA submission.
Tickers: $TSHA
Topics: BLA clinical trials FDA financials R&D